Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 2116 to 2130 of 8937 results

  1. Waldenstrom's macroglobulinaemia - ibrutinib [ID884]

    In development Reference number: GID-TA10046 Expected publication date:  22 November 2017

    Technology appraisal guidance
    In development

  2. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development Reference number: GID-TA11517 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Durvalumab in combination for untreated advanced ovarian, fallopian tube or primary peritoneal cancer before and after surgery [ID6254]

    Awaiting development Reference number: GID-TA11281 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Acalabrutinib for treating relapsed or refractory mantle cell lymphoma [ID6389]

    Awaiting development Reference number: GID-TA11470 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]

    In development Reference number: GID-TA10664 Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. Tislelizumab with chemoradiation for treating localised oesophageal squamous cell cancer [ID5077]

    Awaiting development Reference number: GID-TA10971 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Cabozantinib with atezolizumab for treating hormone-relapsed metastatic prostate cancer after 1 hormonal treatment [ID6387]

    Awaiting development Reference number: GID-TA11438 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. Elinzanetant for treating vasomotor symptoms associated with menopause [ID6359]

    Awaiting development Reference number: GID-TA11428 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Benralizumab for treating hypereosinophilic syndrome in people 12 years and over [ID6322]

    Awaiting development Reference number: GID-TA11360 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Alpelisib for treating severe PIK3CA-related overgrowth spectrum in people 2 years and over [ID6252]

    Awaiting development Reference number: GID-TA11284 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Pembrolizumab with chemoradiotherapy for untreated unresectable oesophageal cancer [ID6270]

    Awaiting development Reference number: GID-TA11303 Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Technologies for the rapid diagnosis of endometriosis

    In development Reference number: GID-HTE10082 Expected publication date:  08 October 2026

    Health technology evaluations
    In development

  13. Epcoritamab for treating relapsed or refractory follicular lymphoma after 2 or more systemic treatments [ID6338]

    In development Reference number: GID-TA11385 Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)

    In development Reference number: GID-NG10216 Expected publication date:  15 July 2026

    NICE guideline
    In development

  15. Atogepant for treating migraine [ID6615]

    In development Reference number: GID-TA11817 Expected publication date:  09 July 2026

    Technology appraisal guidance
    In development